1,303
Views
10
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES

Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer

, , , & ORCID Icon
Pages 102-106 | Received 15 Sep 2017, Accepted 06 Nov 2017, Published online: 04 Dec 2017

Figures & data

Figure 1. Frequency of positive tumors for markers BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67. Immunohistochemical analyzes of markers were interpreted from TMA cores, one central (C) and one peripheral (P), and whole slide sections (W) each from two blocks (1 and 2) from each tumor. All cases have been scored by two observers, 1 and 2, respectively. Only tumors that were interpretable on all cores and sections were included in the analysis.

Figure 1. Frequency of positive tumors for markers BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67. Immunohistochemical analyzes of markers were interpreted from TMA cores, one central (C) and one peripheral (P), and whole slide sections (W) each from two blocks (1 and 2) from each tumor. All cases have been scored by two observers, 1 and 2, respectively. Only tumors that were interpretable on all cores and sections were included in the analysis.

Table 1. Kappa values describing comparisons between immunohistochemial stainings for BCL2, E-Cadherin, EGFR, EMMPRIN (10% cut offs), and Ki67 (20% cut offs) of 108 TMA biopsies and 54 whole slide sections (WS) from 27 breast carcinomas.

Supplemental material

Trine_Tramm_et_al._Supplementary_material.pdf

Download PDF (230.7 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.